FLUOXETINE AND NORFLUOXETINE ARE POTENT INHIBITORS OF P450IID6 - THE SOURCE OF THE SPARTEINE DEBRISOQUINE OXIDATION POLYMORPHISM

被引：111
作者：
BROSEN, K
SKJELBO, E
机构：
[1] Research Center, Orion Pharmaceutica, Espoo
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 1991年 / 32卷 / 01期
关键词：
D O I：
10.1111/j.1365-2125.1991.tb05630.x
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
[No abstract available]
引用
收藏
页码：136 / 137
页数：2
相关论文
共 15 条
[1]  
ARANOW RB, 1989, AM J PSYCHIAT, V146, P911
[2]   FLUOXETINE KINETICS AND PROTEIN-BINDING IN NORMAL AND IMPAIRED RENAL-FUNCTION [J].
ARONOFF, GR ;
BERGSTROM, RF ;
POTTRATZ, ST ;
SLOAN, RS ;
WOLEN, RL ;
LEMBERGER, L .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 36 (01) :138-144
[3]   FLUOXETINE INDUCES ELEVATION OF DESIPRAMINE LEVEL AND EXACERBATION OF GERIATRIC NONPSYCHOTIC DEPRESSION [J].
BELL, IR ;
COLE, JO .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1988, 8 (06) :447-448
[4]  
BORSEN K, 1991, IN PRESS THER DRUG M
[5]   IMIPRAMINE DEMETHYLATION AND HYDROXYLATION - IMPACT OF THE SPARTEINE OXIDATION PHENOTYPE [J].
BROSEN, K ;
OTTON, SV ;
GRAM, LF .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 40 (05) :543-549
[6]   CLINICAL-SIGNIFICANCE OF THE SPARTEINE-DEBRISOQUINE OXIDATION POLYMORPHISM [J].
BROSEN, K ;
GRAM, LF .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 36 (06) :537-547
[7]  
BROSEN K, 1991, IN PRESS CLIN PHARM
[8]  
COWLEY G, 1990, NEWSWEEK 0326
[9]   DEFECTIVE N-OXIDATION OF SPARTEINE IN MAN - NEW PHARMACOGENETIC DEFECT [J].
EICHELBAUM, M ;
SPANNBRUCKER, N ;
STEINCKE, B ;
DENGLER, HJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1979, 16 (03) :183-187
[10]   A FAMILY AND POPULATION STUDY OF THE GENETIC-POLYMORPHISM OF DEBRISOQUINE OXIDATION IN A WHITE BRITISH-POPULATION [J].
EVANS, DAP ;
MAHGOUB, A ;
SLOAN, TP ;
IDLE, JR ;
SMITH, RL .
JOURNAL OF MEDICAL GENETICS, 1980, 17 (02) :102-105
12